New drug CS231295 enters first human trial for tough cancers
NCT ID NCT07612488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find the right dose, and see early signs of whether the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CS231295 (a targeted drug that blocks proteins involved in tumor growth and blood vessel formation)
What this could lead to
If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers that no longer respond to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 42 people, focused mainly on safety and dosing. It is too soon to know if the drug will work, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
Contact
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
Contact
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
Contact